The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Verseon Corporation


Offer details
Expected size of offer (M): 65.8 million
Expected first date of trading: 07/05/2015
Market: AIM
Location of address at which admission document will be available: A copy of the admission document containing full details about Verseon Corporation and the admission of ordinary shares will be available, free of charge, during normal hours on any weekday (except Saturdays, Sundays and public holidays), at the Company's principal place of business at 48820 Kato Road, Suites 100 & 200B, Fremont, California 94538 and at the registered office of King & Spalding International LLP, 125 Old Broad Street, London, EC2N 1AR for a period of a month from the date of Admission and also for download from the Company's website www.verseon.com.
Date at which admission document will be available: -

Advisors
Sponsor: -
Nominated Advisor (AIM Companies): Cenkos Securities plc
Nominated Broker (AIM Companies): Cenkos Securities plc

Company details
Name Role
Thomas Arnold Hecht Non-executive Chairman
Adityo Prakash Adityo Prakash and Eniko Fodor are husband and wife Chief Executive Officer
Eniko Fodor Adityo Prakash and Eniko Fodor are husband and wife Chief Operating Officer & Chief Financial Officer
Grover Turnbow Wickersham Non-executive Director
Alastair Andrew Bertram Cade Non-executive Director

Facts and Figures
Fiscal year end: 31 December
Incorporated in: United States
Website URL: www.verseon.com
space
Description of business:
Verseon is a technology-based pharmaceutical company that employs its proprietary technology to design novel therapeutics for today's challenging diseases. The Company's principal place of business is Fremont, California, United States. Verseon generates multiple, chemically-diverse drug candidates for each discovery programme and, as such, is not reliant on the success or failure of just a ...

Person(s) interested:
Prior to Admission Shareholder Number of Common Shares 1 Percentage of issued share capital Adityo Prakash 31,528,281 28.3% Eniko Fodor 31,002,486 27.8% David Kita 18,157,036 16.3% Godrej Industries Limited 6,694,492 6.0% David Williams 3,490,000 3.1% Assumes conversion by the holder of all Preferred Shares and other classes of common share into Common Shares which are due to become effective on Admission After Admission Shareholder Number of Common Shares 1 Percentage of issued share capital Adityo Prakash 31,528,281 21.1% Eniko Fodor 31,002,486 20.7% David Kita 18,157,036 12.1% Woodford Investment Management LLP 15,712,930 10.5% Godrej Industries Limited2 6,694,492 4.5% Standard Life Investments Limited 4,564,434 3.0% Assumes conversion by the holder of all Preferred Shares and other classes of common share into Common Shares which are due to become effective on Admission 2 On 30 April 2015, the Company received a notice of exercise of warrants in respect of 85,587 shares of Class B Preferred Stock from Godrej Industries. As soon as practicable following Admission, the Company shall issue 171,174 new Common Shares to Godrej Industries in satisfaction of the notice of exercise and receipt of exercise monies. Application will be made for admission to AIM of these shares upon such issue.


Verseon Corporation

Related links

Further informations about 7 and 7/30 days issues can be find by clicking on one of the options below:

Issues last 7 days

Last issues 7/30 days

Back to New and recent issues - Home



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds